Raymond A. Huml, MS, DVM, RAC is Executive Director, Strategic Drug Development and Head, Global Biosimilars Strategic Planning, at Quintiles, Inc. Raymond has a keen interest in MD, including authoring articles and currently working on a Concise Guide to Muscular Dystrophy for Springer Publishing. He is also a supporter of the FSHD (Facioscapulohumeral Muscular Dystrophy) Society. Raymond was previously executive director and head of global due diligence in corporate development for Quintiles Inc. He has more than 20 years of experience in the biopharmaceutical industry, working on major investment transactions involving almost $3.0 billion in capital on alliances with biotechnology and pharmaceutical partners of all sizes. Earlier in his career, Raymond worked in biostatistics, medical writing and regulatory affairs in Quintiles’ clinical development services group. He holds an MS in biology from East Stroudsburg University and a DVM from the North Carolina State University College of Veterinary Medicine, and has earned the RAC (US) certification.